{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:02:39Z","timestamp":1790114559529,"version":"4.0.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1097\/md.0000000000004239","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T11:39:08Z","timestamp":1475667548000},"page":"e4239","source":"Crossref","is-referenced-by-count":48,"title":["Thalidomide for inflammatory bowel disease"],"prefix":"10.1097","volume":"95","author":[{"given":"Matteo","family":"Bramuzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Martelossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Lazzerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-31-20210309","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the treatment of lepra reaction","volume":"6","author":"Sheskin","year":"1965","journal-title":"Clin Pharmacol Ther"},{"key":"R2-31-20210309","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1286-4579(02)01645-3","article-title":"Thalidomide in the treatment of leprosy","volume":"4","author":"Teo","year":"2002","journal-title":"Microbes Infect"},{"key":"R3-31-20210309","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaad.2015.01.002","article-title":"Review of thalidomide use in the pediatric population","volume":"72","author":"Yang","year":"2015","journal-title":"J Am Acad Dermatol J Am Acad Dermatol"},{"key":"R4-31-20210309","first-page":"CD007351","article-title":"Thalidomide and thalidomide analogues for maintenance of remission in Crohns disease.","volume":"2","author":"Akobeng","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-31-20210309","first-page":"CD007350","article-title":"Thalidomide and thalidomide analogues for induction of remission in Crohns disease.","volume":"2","author":"Srinivasan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-31-20210309","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/apt.13181","article-title":"Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease","volume":"41","author":"Yang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-31-20210309","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.cgh.2015.10.034","article-title":"Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease","volume":"14","author":"Simon","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R10-31-20210309","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.2013.280777","article-title":"Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial","volume":"310","author":"Lazzerini","year":"2013","journal-title":"JAMA"},{"key":"R11-31-20210309","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/apt.13057","article-title":"Long-term outcomes of thalidomide in refractory Crohn's disease","volume":"41","author":"Gerich","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-31-20210309","first-page":"726","article-title":"An analysis of adverse drug reactions of thalidomide in treatment of immune-related bowel diseases","volume":"52","author":"Luo","year":"2013","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R13-31-20210309","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2036.2006.03211.x","article-title":"Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results","volume":"25","author":"Lazzerini","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R14-31-20210309","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2036.2006.03239.x","article-title":"Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies","volume":"25","author":"Plamondon","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R15-31-20210309","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/MIB.0000000000000437","article-title":"Effect of thalidomide on clinical remission in children and adolescents with ulcerative colitis refractory to other immunosuppressives: pilot randomised clinical trial","volume":"21","author":"Lazzerini","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R16-31-20210309","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","article-title":"Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial","volume":"117","author":"Ehrenpreis","year":"1999","journal-title":"Gastroenterology"},{"key":"R17-31-20210309","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(14)61621-8","article-title":"Clinical efficacy and mechanism of action of thalidomide in pediatric patients with refractory Crohn's disease","volume":"146","author":"Leung","year":"2014","journal-title":"Gastroenterology"},{"key":"R18-31-20210309","first-page":"183","article-title":"Thalidomide in immunosuppressors and anti-TNF unresponsive Crohn's disease patients: efficacy and side effects","volume":"3","author":"Scribano","year":"2011","journal-title":"J Crohn's Colitis"},{"key":"R19-31-20210309","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1046\/j.1365-2036.2002.01273.x","article-title":"An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease","volume":"16","author":"Sabate","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-31-20210309","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1016\/S1873-9946(14)60556-0","article-title":"Intravenous cyclophosphamide combined with thalidomide has a promising effect in refractory Crohn's disease","volume":"8","author":"Tang","year":"2014","journal-title":"J Crohn's Colitis"},{"key":"R21-31-20210309","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","article-title":"An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease","volume":"117","author":"Vasiliauskas","year":"1999","journal-title":"Gastroenterology"},{"key":"R22-31-20210309","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MPG.0b013e318228349e","article-title":"Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab","volume":"54","author":"Felipez","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R23-31-20210309","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1440-1746.2002.02564.x","article-title":"Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease","volume":"17","author":"Bariol","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R24-31-20210309","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.50.2.196","article-title":"Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease","volume":"50","author":"Bauditz","year":"2002","journal-title":"Gut"},{"key":"R25-31-20210309","first-page":"A767","article-title":"Thalidomide-effective therapy in chronic resistant inflammatory bowel disease","volume":"116","author":"Macumber","year":"1999","journal-title":"Gastroenterology"},{"key":"R26-31-20210309","first-page":"338","article-title":"Thalidomide for refractory Crohn's disease failing infliximab","volume":"37","author":"Gupta","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R27-31-20210309","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/ajg.2009.509","article-title":"Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas","volume":"104","author":"Ng","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R28-31-20210309","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1590-8658(14)60074-8","article-title":"Association of thalidomide with anti-TNF-\u03b1 therapy in Crohn's disease patients who lost response to anti-TNF-\u03b1: A case series","volume":"46","author":"Scribano","year":"2014","journal-title":"Dig Liver Dis"},{"key":"R29-31-20210309","doi-asserted-by":"crossref","first-page":"A582","DOI":"10.1016\/S0016-5085(00)84466-2","article-title":"Open labeled pilot study of thalidomide(thal) as a novel therapy for medically resistant ulcerative colitis (UC)","volume":"118","author":"Kam","year":"2000","journal-title":"Gastroenterology"},{"key":"R30-31-20210309","first-page":"110","article-title":"Thalidomide treatment for maintainance of infliximab induced response in refractory paediatric Crohn's disease","volume":"44","author":"Srinivasan","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R31-31-20210309","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00005176-200310000-00023","article-title":"Thalidomide in Crohn disease and the risk of peripheral neuropathy","volume":"37","author":"Ahmed","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R32-31-20210309","first-page":"A89","article-title":"An open trial of thalidomide in refractory Crohn's colitis","volume":"48","author":"Trebble","year":"2001","journal-title":"Gut"},{"key":"R33-31-20210309","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3748\/wjg.v17.i10.1286","article-title":"Treatment of pediatric refractory Crohn's disease with thalidomide","volume":"17","author":"Zheng","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R34-31-20210309","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1067\/moe.2002.113","article-title":"Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis","volume":"95","author":"Hegarty","year":"2003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"R35-31-20210309","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.dld.2014.12.012","article-title":"Orofacial granulomatosis in children: think about Crohn's disease","volume":"47","author":"Lazzerini","year":"2015","journal-title":"Dig Liver Dis"},{"key":"R36-31-20210309","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00004836-200208000-00006","article-title":"Thalidomide as \u201csalvage\u201d therapy for patients with delayed hypersensitivity response to infliximab: a case series","volume":"35","author":"Kane","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"R37-31-20210309","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1155\/2004\/296736","article-title":"Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy","volume":"18","author":"Cohen","year":"2004","journal-title":"Can J Gastroenterol"},{"key":"R38-31-20210309","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/gut.2003.029710","article-title":"Thalidomide for treatment of severe intestinal bleeding","volume":"53","author":"Bauditz","year":"2004","journal-title":"Gut"},{"key":"R39-31-20210309","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.nmd.2004.10.005","article-title":"Thalidomide neuropathy in childhood","volume":"15","author":"Fleming","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"R40-31-20210309","first-page":"A629","article-title":"Long term efficacy and toxicity of thalidomide in Crohn's disease","volume":"126","author":"Simon","year":"2004","journal-title":"Gastroenterology"},{"key":"R41-31-20210309","doi-asserted-by":"crossref","first-page":"S435","DOI":"10.1016\/S0016-5085(13)61602-9","article-title":"Efficacy and safety of thalidomide in Chinese patients with refractory Crohn's disease","volume":"144","author":"Qian","year":"2013","journal-title":"Gastroenterology"},{"key":"R42-31-20210309","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00005176-200102000-00016","article-title":"Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results","volume":"32","author":"Facchini","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R43-31-20210309","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/MCG.0000000000000122","article-title":"Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-\u03b1 drugs: report of 3 cases and literature review","volume":"48","author":"Scribano","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"R44-31-20210309","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1002\/ibd.22845","article-title":"Amenorrhea in women treated with thalidomide: report of two cases and literature review","volume":"19","author":"Lazzerini","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R45-31-20210309","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J Support Oncol"},{"key":"R46-31-20210309","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","article-title":"Thalidomide-induced neuropathy","volume":"59","author":"Chaudhry","year":"2002","journal-title":"Neurology"},{"key":"R47-31-20210309","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/WNL.62.12.2291","article-title":"Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study","volume":"62","author":"Cavaletti","year":"2004","journal-title":"Neurology"},{"key":"R48-31-20210309","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","article-title":"Thalidomide Neuropathy Study Group. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients","volume":"119","author":"Bastuji-Garin","year":"2002","journal-title":"J Invest Dermatol"},{"key":"R49-31-20210309","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pediatrneurol.2007.11.004","article-title":"Childhood thalidomide neuropathy: a clinical and neurophysiologic study","volume":"38","author":"Priolo","year":"2008","journal-title":"Pediatr Neurol"},{"key":"R50-31-20210309","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"R51-31-20210309","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/ibd.21563","article-title":"Thromboembolism in pediatric inflammatory bowel disease: systematic review","volume":"17","author":"Lazzerini","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R52-31-20210309","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2036.2007.03385.x","article-title":"A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease","volume":"26","author":"Mansfield","year":"2007","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000004239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:28:59Z","timestamp":1620959339000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201607260-00031"}},"subtitle":["Systematic review"],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":50,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004239","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}